{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:28:15Z","timestamp":1788917295408,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.urolonc.2020.07.028","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T09:15:40Z","timestamp":1606382140000},"page":"194.e1-194.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma"],"prefix":"10.1016","volume":"39","author":[{"given":"Claudia","family":"Kesch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Bidnur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Thi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Beraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Moskalev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Yago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Adomat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Fazli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Gleave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.07.028_bib0001","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0002","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0022-5347(05)67019-X","article-title":"Upper tract urothelial neoplasms: incidence and survival during the last 2 decades","volume":"164","author":"Munoz","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0003","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update","volume":"73","author":"Roupr\u00eat","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0004","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11912-018-0727-5","article-title":"Molecular subtypes of bladder cancer","volume":"20","author":"McConkey","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0006","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.urolonc.2019.02.004","article-title":"Endocavitary treatment for upper tract urothelial carcinoma: a meta-analysis of the current literature","volume":"37","author":"Foerster","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0007","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non\u2013muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0008","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0009","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/0300985811402846","article-title":"Swine as models in biomedical research and toxicology testing","volume":"49","author":"Swindle","year":"2012","journal-title":"Vet Pathol"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0010","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/S0022-5347(01)64902-4","article-title":"Microscopic study of the pig ureteral urothelium","volume":"157","author":"Desgrandchamps","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0011","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0012","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0013","article-title":"Complications of ureteroscopy: a complete overview","author":"De Coninck","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective","volume":"78","author":"Ciccolini","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0015","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1179\/joc.2007.19.2.212","article-title":"Clinical phase I and pharmacology study of gemcitabine (2\u2019, 2\u2019-difluorodeoxycytidine) administered in a two-weekly schedule","volume":"19","author":"Peters","year":"2007","journal-title":"J Chemother"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0016","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/17512433.2018.1461560","article-title":"Intracavitary therapies for upper tract urothelial carcinoma","volume":"11","author":"Knoedler","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0017","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0022-5347(05)64454-0","article-title":"Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery","volume":"168","author":"Thalmann George","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0018","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4103\/0974-7796.115746","article-title":"Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma","volume":"5","author":"Aboumarzouk","year":"2013","journal-title":"Urol Ann"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0019","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0090-4295(01)01488-1","article-title":"Intravesical instillation of bacille Calmette-Gu\u00e9rin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter","volume":"59","author":"Irie","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0020","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.urology.2016.09.039","article-title":"Sustained-release formulation of mitomycin C to the upper urinary tract using a thermosensitive polymer: a preclinical study","volume":"99","author":"Donin","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0021","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.urolonc.2016.11.019","article-title":"Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: safety and feasibility","volume":"35","author":"Donin","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0022","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1470-2045(20)30147-9","article-title":"Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial","volume":"21","author":"Kleinmann","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0023","doi-asserted-by":"crossref","first-page":"40.e1","DOI":"10.1016\/j.urolonc.2013.04.006","article-title":"Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection","volume":"32","author":"Filson","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2020.07.028_bib0024","series-title":"NCCN Guidelines Version 4.2019 for Bladder Cancer","author":"Flaig","year":"2019"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:19:39Z","timestamp":1761041979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920303744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1078143920303744"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.028","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}